Nonsurgical Management of Cervical Cancer: Locally Advanced, Recurrent, and Metastatic Disease, Survivorship, and Beyond

Abstract

Overview Despite the declining incidence of cervical cancer as a result of the introduction of screening programs, globally it remains a leading cause of cancer-related death in women. Outcomes for patients who are diagnosed with anything but early-stage disease remain poor. Here we examine emerging strategies to improve the treatment of locally advanced disease. We discuss emerging biologic data, which are informing our investigation of new therapeutic interventions in persistent, recurrent, and metastatic cervical cancer. We recognize the importance of interventions to improve quality of life and to prevent long-term sequelae in women undergoing treatment. Finally, and perhaps most importantly, we recognize the need for global collaboration and advocacy to improve the outcome for all women at risk of and diagnosed with this disease.

Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand

“…The five-year overall survival of the advanced and recurrent cervical cancer who were treated with chemotherapy in the present study was 15.2% and the median overall survival was 13.2 months that corresponded with the previous literature review that showed the five year-survival rate between 5% and 15% and the median overall survival at 12 months (Mackay et al, 2015). The most common first line chemotherapy regimen in the present study was cisplatin plus 5FU that achieved objective response at 42.4%.…”

“…However, the recurrence rate and persistent disease still developed in about one-third of all cervical cancer patients especially in the advanced stage (Peiretti et al, 2012;Micha et al, 2015). The main treatment for these recurrent, persistent and also the advanced stage patients is cisplatin-based chemotherapy ( (Kamura and Ushijima ,2013;Mackay et al, 2015). Various drugs were tested to combine with cisplatin such as ifosfamide, 5-fluorouracil (5FU), paclitaxel, gemcitabine, vinorelbine, topotecan with the aim to improve survival in the clinical trials and only paclitaxel seemed to gain a survival benefit and showed the least adverse effects than other drugs with the response rate of 29% and the median progression-free survival and overall survival were 5.8 months and 12.9 months, respectively (Monk et al, 2009 Kuanoon Boupaijit, Prapaporn Suprasert* combined with paclitaxel was accepted as the standard treatment for these recurrence patients (Pfaendler and Tewari, 2016).…”

The clinical and prognostic value of CXCL8 in cervical carcinoma patients: immunohistochemical analysis

“…Nowadays, operation or radiotherapy combined with chemotherapy is a major treatment for cervical cancer patients [ 4 , 5 ]. Effective target therapy is destitute in cervical cancer [ 6 , 7 ]. Therefore, it is necessary to explore novel biomarkers for predicting clinical outcome and developing therapeutic target in cervical cancer patients.…”

Awareness about Early Detection Methods, Symptoms and Risk Factors towards Breast and Cervical Cancer among the Female Students of Mawlana Bhashani Science and Technology University (MBSTU), Santosh, Tangail, Bangladesh

“…Several challenges face cervical cancer screening programs and help-seeking for cervical cancer in South Asia [33]. Despite the declining incidence of cervical cancer as a result of the introduction of screening programs, globally still now it remains a leading cause of cancer-related death in women [34]. Moreover, the age distribution of cervical cancer is changing and many studies regarding appropriate commencing age of screening are being reported [35].…”